CSTL vs GH
CSTL: Castle Biosciences provides specialized molecular diagnostic tests to improve risk stratification and personalized treatment decisions for patients with skin cancers, Barrett's esophagus, and atopic dermatitis. GH: Guardant Health is a precision oncology company transforming cancer care with FDA-approved blood and tissue tests powered by AI analytics that span early detection, treatment selection, and disease monitoring.
Side-by-side fundamentals
| Metric | CSTL | GH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.81 | $150.75 | |
| Market cap as of 2026-07-23 | $749M | $19.8B | |
| PEG as of 2026-07-23 | -0.49 | -71.05 | GH lower |
| Net margin as of 2026-07-23 | -3.8% | -40.1% | CSTL higher |
| Gross margin as of 2026-07-23 | +77.9% | +64.9% | CSTL higher |
| Operating margin as of 2026-07-23 | -9.8% | -42.7% | CSTL higher |
| ROE as of 2026-07-23 | -2.8% | -246.6% | CSTL higher |
| ROA as of 2026-07-23 | -2.3% | -26.5% | CSTL higher |
| Debt / equity as of 2026-07-23 | 0.03 | 16.78 | CSTL lower |
| Revenue growth (YoY) as of 2026-07-23 | -2.1% | +39.6% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +35.9% | +29.8% | CSTL higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.02 | 1.63 | |
| 1-year return as of 2026-07-22 close | +52.0% | +225.9% | GH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.